Literature DB >> 11088036

Comparative efficacy of teicoplanin and cefazolin for cardiac operation prophylaxis in 3027 patients. The ESPRIT Group.

R Saginur1, D Croteau, M G Bergeron.   

Abstract

OBJECTIVE: Cephalosporins, especially cefazolin, are widely used in the prevention of postoperative wound infections after cardiac operations. As more and more Staphylococcus aureus and Staphylococcus epidermidis strains are becoming resistant to cephalosporins and other antibiotics, alternative agents, such as glycopeptides, are often used as prophylaxis. We performed a multicenter double-blind randomized controlled trial comparing teicoplanin, a glycopeptide antibiotic, with cefazolin.
METHODS: A total of 3027 adult patients undergoing elective coronary artery bypass grafting, valve operations, or both were randomized to a single dose of teicoplanin (15 mg/kg) or a 2-day course of cefazolin (2 g initial dose, followed by 1 g every 8 hours for 6 more doses). Patients were followed up for a total of 6 months postoperatively. The primary objective was to compare, between groups, the incidence of surgical infections up to 30 days postoperatively. Secondary objectives were incidence of other infections, other complications, and death.
RESULTS: A total of 3027 patients were randomized to receive either teicoplanin (n = 1518) or cefazolin (n = 1509). Thirty days postoperatively, there was a trend to more deep sternotomy wound infections in the teicoplanin group (31 vs 18, P =. 087), which became significant by 6 months (36 vs 19, P =.032). One hundred percent of the gram-positive strains infecting patients were susceptible to teicoplanin, whereas 8.3% were resistant to cefazolin. Pneumonia and urinary tract infections were more common in the teicoplanin group. Deep wound infections of the leg were more common in the cefazolin group.
CONCLUSIONS: Cefazolin was more effective prophylaxis than teicoplanin against postoperative wound infections after elective cardiac operations. Infection rates were low with either treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11088036     DOI: 10.1067/mtc.2000.110384

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  A national survey of antimicrobial prophylaxis in adult cardiac surgery across Canada.

Authors:  Fran L Paradiso-Hardy; Patti Cornish; Chantal Pharand; Stephen E Fremes
Journal:  Can J Infect Dis       Date:  2002-01

2.  Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery.

Authors:  Loren G Miller; James A McKinnell; Michael E Vollmer; Brad Spellberg
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

Review 3.  Infectious complications of cardiac surgery: a clinical review.

Authors:  Matthew E Cove; Denis W Spelman; Graeme MacLaren
Journal:  J Cardiothorac Vasc Anesth       Date:  2012-07-04       Impact factor: 2.628

Review 4.  2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents.

Authors:  Georgeta Serban; Oana Stanasel; Sanda Bota; Eugenia Serban
Journal:  Drug Des Devel Ther       Date:  2018-05-31       Impact factor: 4.162

Review 5.  Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis.

Authors:  Marin Schweizer; Eli Perencevich; Jennifer McDanel; Jennifer Carson; Michelle Formanek; Joanne Hafner; Barbara Braun; Loreen Herwaldt
Journal:  BMJ       Date:  2013-06-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.